Skip to main content
. Author manuscript; available in PMC: 2019 Apr 9.
Published in final edited form as: Sci Transl Med. 2018 Aug 29;10(456):eaam6474. doi: 10.1126/scitranslmed.aam6474

Fig. 7. Effects of tenapanor on NaPi2b expression in rats and NaPi2b activity in mouse ileum monolayer cultures and in vivo in mice.

Fig. 7.

(A) NaPi2b mRNA expression in different intestinal segments after 14 days of tenapanor (0.5 mg/kg) or vehicle (acidified water, 0.01% Tween 80) treatment in rats (n = 8 per group). (B) Immunohistochemistry showing NaPi2b expression in rat jejunum after in vivo treatment with tenapanor or vehicle. (C) Apical and basolateral phosphate concentrations after overnight incubation at different initial apical phosphate concentrations (1 to 5 mM) in mouse ileum monolayer cultures with initial basolateral phosphate concentration of 1 mM (n = 6 per group). (D) Apical phosphate concentrations after a 4-hour, 2-day, or 3-day incubation with tenapanor (1 μM), NTX-9066 (NaPi2b inhibitor; 1 μM), or vehicle (DMSO) in mouse ileum monolayer cultures (n = 6 per group). BQL, below quantification limit. (E) Phosphate absorption with tenapanor (10 μM) versus vehicle in NaPi2b KO and control [wild-type (WT)] mouse ileum in an in vivo ileum loop model (n = 4 to 5 per group). Means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; two-way ANOVA, with post hoc testing at each segment with Bonferroni’s correction (A); one-way ANOVA, with post hoc testing at each concentration (C) or time point (D) with Bonferroni’s correction.